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Editorial on the Research Topic
EBV-Associated Carcinomas: Presence, Role and Prevention Strategies
This special issue addresses an important topic related to the role of Epstein-Barr virus (EBV) in
human carcinomas initiation and progression, which is one of the most common viral infections
worldwide. Today, the relationship between EBV infection and several types of human lymphomas
is clearly established, including Hodgkin and Burkitt’s lymphoma; meanwhile, it was recently
pointed out that EBV is present in nasopharyngeal carcinomas as well as other epithelial cancers
(1). EBV is ubiquitous human herpesvirus 4, its genome codes more than 85 proteins of which
only few are well-understood; More specifically, six nuclear antigens (EBNA: 1, 2, 3A, 3B, 3C, and
LP); three latent membrane proteins/genes (LMP: 1, 2A, 2B) as well as small non-polyadenylated
RNAs, EBERs 1 and 2 in addition to few microRNAs have been identified so far, as key regulators,
of the oncogenic activity of this virus (2, 3). Present estimates indicate that EBV causes 200,000
new cancer cases annually, accounting for ∼2% of cancers worldwide (Cancer Research UK). On
the other hand, it is important to emphasize that recent investigations have revealed the possible
involvement of EBV in other cancers such as cervical, gliomas, and breast, which are highlighted in
this issue.
This topic comprises ninemanuscripts that cover the involvement of EBV in human carcinomas.
Within this special issue the reader will become familiar with the most studied EBV oncoproteins
and their role in carcinogenesis. More specifically, El-Sharkawy et al. discuss the role of LMP1
and LMP2A as well as EBV nuclear antigens (EBNAs) in EBV persistence and latency infection.
Moreover, the authors highlight the roles of these oncoproteins in activating different signal
transduction pathways which are critical for cell growth and survival and can present a potential
therapeutic target for EBV-associated cancers. While, Smatti et al. provide a review of EBV
epidemiology and genetic variability of the LMP1 oncoprotein. They also detail the most recent
findings of EBV seroprevalence and viremia studies specially in healthy blood donors as a highly
prevalent way of transmitting oncoviruses including EBV.
An up-to-date account of the role of EBV in several known carcinomas are also covered, starting
with the presence of EBV in cervical cancer in a review paper by Vranic et al. then, in gliomas by
Akhtar et al. breast cancer by Abdallah et al. as well as head and neck (HN) cancer by Fernandes
et al. More specifically, the reader will perceive the controversy of this virus being associative,
causative, or an experimental artifact in clinical literature, and the conflicting data results on the
presence of EBV in gliomas (Akhtar et al.). In addition, the important issue of immunological
aspects underlying the infection by this oncovirus and the use of immunotherapeutic interventions
as a potential modality for targeting EBV-associated HN cancers (Fernandes et al.). Moreover,
according to Abdallah et al. there is no doubt in the pathogenic role of EBV in breast cancer,
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as their pilot genome-wide methylome study in breast cancer
samples from Sudan identified clear genetic differences between
primary tumor samples and adjacent normal tissues from
the same patients. Differential methylation analysis revealed
developmental and viral pathways dysregulations, including EBV
infection, that can be used for targeted therapies of breast cancer.
On the other hand, possible interactions between EBV and other
oncoviruses, such as HPVs are touched upon by Vranic et al.
implicating the role of co-infection in the full development of
cervical cancer pathogenesis. EBV and HPVs co-presence in
cervical cancer was confirmed in the original research paper
presented by Al-Thawadi et al. that investigated this aspect in
cervical cancer samples from Syrian women. Based on their
study, EBV and high-risk HPVs are associated with highly
aggressive cancer phenotype in human cervical cancer, which
begs for extensive research into the cooperation between these
two common oncoviruses.
The cooperative role of EBV and high-risk HPVs is
fully addressed by Cyprian et al. detailing their possible
role in the initiation and/or amplification of epithelial to
mesenchymal transition (EMT), which is the hallmark of cancer
progression. The authors propose that this cooperation can
occur via β-catenin, JAK/STAT/SRC, PI3k/Akt/mTOR, and/or
RAS/MEK/ERK signaling pathways as both EBV andHPVs share
these paths.
Finally, Khan et al. present an original research paper on
the role of Skp2 and its ubiquitin-proteasome pathway in HN
carcinomas. They found that treatment of HN cancer cells
with curcumin or transfection of small interfering RNA of
Skp2, causes down-regulation of Skp2 in HPV+, HPV– cells.
Additionally, treatment with curcumin induced apoptosis via
mitochondrial pathway and activation of caspases. While, co-
treatment of HN cancer cells with curcumin and cisplatin also
inhibited cell viability and apoptotic effects. This is an interesting
finding since an important part of HN cancers, the majority of
oral cancers, are positive for EBV; thus, we believe that this kind
of study can be extended to EBV or EBV/HPV positive human
carcinomas.
This collection of manuscripts addresses important health
gaps with regards to the role of EBV infection in human
carcinomas which are of global interest, as increasing number
of malignancies are linked to EBV infection, and the majority
of these cases occur in developing countries. Therefore, studies
combined with awareness campaigns that emphasize the role
of simple hygienic measures as a cancer prevention strategy;
in addition to understanding the importance of the upcoming
EBV vaccine may play a crucial role in the prevention and
reduction of EBV related cancers (4). On the other hand, more
investigations, on cellular and molecular level, are necessary to
elucidate the oncogenic role of EBV in human carcinomas. More
specifically, crosstalk between EBV and other oncoviruses such
as high-risk HPVs is an important topic that should be taken into
consideration since it is well-know that oncogenesis is a complex
process involving several oncogenes (c-onc and v-onc) as well as
other factors.
Finally, we are thankful to the authors of these manuscripts
who have responded and enriched the topic with their valuable
contributions. The findings of these manuscripts are interesting
and contribute to our understanding of the complex role of EBV
in human carcinomas.
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